A nephron-based model of the kidneys for macro-to-micro α-particle dosimetry

Physics in Medicine and Biology

Volumn 57, Issue 13, 2012, Pages 4403-4424

  Hobbs, Robert F ^a   Song, Hong ^a   Huso, David L ^b   H Sundel, Margaret ^a   Sgouros, George ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL APPLICATION; CRITICAL STEPS; EX-VIVO; GEOMETRICAL MODELS; GEOMETRICAL SHAPES; HIGH LINEAR ENERGY TRANSFERS; HUMAN MODEL; MACROSCOPIC LEVELS; MICRO-SCALES; MICROSCALE SUBSTRUCTURES; MONTE CARLO SIMULATION; MURINE MODEL; PARTICLE THERAPY; PATH LENGTH; POTENTIAL EFFICACY; PRE-CLINICAL; RENAL CORTEX; TREATMENT MODALITY;

ISOTOPES; MAMMALS; MONTE CARLO METHODS; TOXICITY;

DOSIMETRY;

ALPHA RADIATION; ANIMAL; ARTICLE; BIOLOGICAL MODEL; HUMAN; IMAGE QUALITY; METHODOLOGY; MONTE CARLO METHOD; MOUSE; NEPHRON; RADIATION EXPOSURE; RADIOMETRY;

ALPHA PARTICLES; ANIMALS; HUMANS; MICE; MODELS, BIOLOGICAL; MONTE CARLO METHOD; NEPHRONS; PHANTOMS, IMAGING; RADIOMETRY;

EID: 84862728854     PISSN: 00319155     EISSN: 13616560     Source Type: Journal    
DOI: 10.1088/0031-9155/57/13/4403     Document Type: Article

References (57)

1. Agostinelli S et al 2003 GEANT4a simulation toolkit Nucl. Instrum. Methods Phys. Res. A 506 250303
2. Akabani G, Kennel S J and Zalutsky M R 2003 Microdosimetric analysis of alpha-particle-emitting targeted radiotherapeutics using histological images J. Nucl. Med. 44 792805 (Pubitemid 39655215)
3. Akabani G and Zalutsky M R 1997 Microdosimetry of astatine-211 using histological images: application to bone marrow Radiat. Res. 148 599607 (Pubitemid 27527750)
4. Andersson H et al 2009 Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of (211)At-MX35 F(ab')2a phase I study J. Nucl. Med. 50 115360
5. Arazi L, Cooks T, Schmidt M, Keisari Y and Kelson I 2010 The treatment of solid tumors by alpha emitters released from (224)Ra-loaded sources-internal dosimetry analysis Phys. Med. Biol. 55 120318
6. Aurlien E, Larsen R H, Akabani G, Olsen D R, Zalutsky M R and Bruland O S 2000 Exposure of human osteosarcoma and bone marrow cells to tumour-targeted alpha-particles and gamma-irradiation: analysis of cell survival and microdosimetry Int. J. Radiat. Biol. 76 112941 (Pubitemid 30488622)
7. Back T and Jacobsson L 2010 The alpha-camera: a quantitative digital autoradiography technique using a charge-coupled device for ex vivo high-resolution bioimaging of alpha-particles J. Nucl. Med. 51 161623
8. Back T et al 2009 Glomerular filtration rate after alpha- radioimmunotherapy with 211At-MX35-F(ab')2: a long-term study of renal function in nude mice Cancer Biother. Radiopharm. 24 64958
9. Barone R et al 2005 Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship J. Nucl. Med. 46 99S106S
10. Behr T M, Behe M and Sgouros G 2002 Correlation of red marrow radiation dosimetry with myelotoxicity: empirical factors influencing the radiation-induced myelotoxicity of radiolabeled antibodies, fragments and peptides in pre-clinical and clinical settings Cancer Biother. Radiopharm. 17 44564
11. Bhathena D B 1993 Glomerular size and the association of focal glomerulosclerosis in long-surviving human renal allografts J. Am. Soc. Nephrol. 4 131626
12. Bolch W E et al 1999 MIRD pamphlet no. 17: the dosimetry of nonuniform activity distributionsradionuclide S values at the voxel level. Medical Internal Radiation Dose Committee J. Nucl. Med. 40 11S36
13. Bolch W E, Eckerman K F, Sgouros G and Thomas S R 2009 MIRD pamphlet no. 21: a generalized schema for radiopharmaceutical dosimetrystandardization of nomenclature J. Nucl. Med. 50 47784
14. Bouchet L G et al 2003 MIRD pamphlet no 19: absorbed fractions and radionuclide S values for six age-dependent multiregion models of the kidney J. Nucl. Med. 44 111347 (Pubitemid 40003745)
15. Brindle J M, Trindade A A, Pichardo J C, Myers S L, Shah A P and Bolch W E 2006 CT volumetry of the skeletal tissues Med. Phys. 33 3796803 (Pubitemid 44505104)
16. Chouin N et al 2009a Evidence of extranuclear cell sensitivity to alpha-particle radiation using a microdosimetric model : II. Application of the microdosimetric model to experimental results Radiat. Res. 171 66473
17. Chouin N et al 2009b Evidence of extranuclear cell sensitivity to alpha-particle radiation using a microdosimetric model : I. Presentation and validation of a microdosimetric model Radiat. Res. 171 65763
18. Chu S, Ekström L and Firestone R 1999 WWW Table of Radioactive Isotopes http://nucleardata.nuclear.lu.se/nucleardata/toi/
19. Cristy M and Eckerman K 1987 Specific Absorbed Fractions of Energy at Various Ages for Internal Photon Sources (Oak Ridge, TN: Oak Ridge National Laboratory)
20. 90Y-tiuexetan-ibritumomab versus external beam X-radiation Int. J. Radiat. Oncol. Biol. Phys. 72 18692
21. De Jong M et al 2004 Inhomogeneous localization of radioactivity in the human kidney after injection of [(111)In-DTPA]octreotide J. Nucl. Med. 45 116871 (Pubitemid 47611662)
22. Dorph-Petersen K A, Nyengaard J R and Gundersen H J 2001 Tissue shrinkage and unbiased stereological estimation of particle number and size J. Microsc. 204 23246 (Pubitemid 34075121)
23. 213Bi]anti-CD45 antibodies in leukemia cells Cancer Res 67 19508 (Pubitemid 46424211)
24. Henriksen G, Breistol K, Bruland O S, Fodstad O and Larsen R H 2002 Significant antitumor effect from bone-seeking, alpha-particle-emitting (223)Ra demonstrated in an experimental skeletal metastases model Cancer Res. 62 31205 (Pubitemid 34605984)
25. 89Sr in mice J. Nucl. Med. 44 2529
26. Hobbs R et al 2011 A model of cellular dosimetry for macroscopic tumors in radiopharmaceutical therapy Med. Phys. 38 2892903
27. 223Ra alpha-emitter radiopharmaceutical therapy Phys. Med. Biol. 57 320722
28. Hobbs R F et al 2010 Arterial wall dosimetry for non-Hodgkin lymphoma patients treated with radioimmunotherapy J. Nucl. Med. 51 36875
29. Imam S K 2001 Advancements in cancer therapy with alpha-emitters: a review Int. J. Radiat. Oncol. Biol. Phys. 51 2718 (Pubitemid 32758888)
30. Jaggi J S et al 2005a Efforts to control the errant products of a targeted in vivo generator Cancer Res. 65 488895 (Pubitemid 40740828)
31. Jaggi J S, Seshan S V, McDevitt M R, LaPerle K, Sgouros G and Scheinberg D A 2005b Renal tubulointerstitial changes after internal irradiation with alpha-particle-emitting actinium daughters J. Am. Soc. Nephrol. 16 267789
32. Jaggi J S, Seshan S V, McDevitt M R, Sgouros G, Hyjek E and Scheinberg D A 2006 Mitigation of radiation nephropathy after internal alpha-particle irradiation of kidneys Int. J. Radiat. Oncol. Biol. Phys. 64 150312
33. Jamison R L 1973 Intrarenal heterogeneity. The case for two functionally dissimilar populations of nephrons in the mammalian kidney Am. J. Med. 54 2819
34. Jurcic J G et al 2002 Targeted alpha-particle immunotherapy for myeloid leukemia Blood 100 12339 (Pubitemid 34864277)
35. Jurcic J G et al 2006 Alpha-particle immunotherapy for acute myeloid leukemia (AML) with bismuth-213 and actinium-225 Cancer Biother. Radiopharm. 21 396
36. Kneifel S et al 2006 Local targeting of malignant gliomas by the diffusible peptidic vector 1,4,7,10-tetraazacyclododecane-1-glutaric acid-4,7,10-triacetic acid-substance P Clin. Cancer Res. 12 384350 (Pubitemid 44000266)
37. Larsson E, Meerkhan S A, Strand S E and Jonsson B A 2011 A small-scale anatomic model for testicular radiation dosimetry for radionuclides localized in the human testes J. Nucl. Med. 53 7281
38. Lewington V J et al 2010 Alpharadin: a novel, targeted approach for treatment of bone metastases from CRPC-calculated alpha-particle dosimetry compared to a favorable clinical safety profile ASCO Genitourinary Cancers Symp. (San Francisco, CA, USA,)
39. Loevinger R, Budinger T F and Watson E E 1991 MIRD Primer for Absorbed Dose Calculations (New York, NY: The Society of Nuclear Medicine, Inc.)
40. McDevitt M R et al 2000 An alpha-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer Cancer Res. 60 6095100
41. McDevitt M R et al 1998 Radioimmunotherapy with alpha-emitting nuclides Eur. J. Nucl. Med. 25 134151 (Pubitemid 28446064)
42. Nyengaard J R and Bendtsen T F 1992 Glomerular number and size in relation to age, kidney weight, and body surface in normal man Anat. Rec. 232 194201
43. 206Bi in the normal rat Radiat. Res. 63 44354
44. Sato F, Tsuchihashi S and Kawashima N 1975 Age changes in number and size of the murine renal glomeruli Exp. Gerontol. 10 32531
45. Schwartz J et al 2011 Renal uptake of bismuth-213 and its contribution to kidney radiation dose following administration of actinium-225-labeled antibody Phys. Med. Biol. 56 72133
46. 195 (anti-CD33) in patients with leukemia J. Nucl. Med. 40 193546 (Pubitemid 29523591)
47. Sgouros G et al 2010 MIRD pamphlet no. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy J. Nucl. Med. 51 31128
48. Snyder W S, Ford M R, Warner G G and Watson S B 1975 S, Absorbed Dose Per Unit Cumulated Activity for Selected Radionuclides and Organs. MIRD Pamphlet No. 11 (New York: Society of Nuclear Medicine)
49. 90Y Cancer Res. 69 89418
50. Song H et al 2008 213Bi (alpha-emitter)-antibody targeting of breast cancer metastases in the neu-N transgenic mouse model Cancer Res. 68 387380
51. Stabin M G, Sparks R B and Crowe E 2005 OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine J. Nucl. Med. 46 10237 (Pubitemid 43733519)
52. Taketo M et al 1991 FVB/N: an inbred mouse strain preferable for transgenic analyses Proc. Natl Acad. Sci. USA 88 20659 (Pubitemid 21916354)
53. Wessels B W et al 2008 MIRD pamphlet no 20: the effect of model assumptions on kidney dosimetry and responseimplications for radionuclide therapy J. Nucl. Med. 49 188499
54. Zalutsky M R et al 2001 Radioimmunotherapy of recurrent glioma patients using alpha-particle emitting astatine-211 labeled chimeric anti-tenascin monoclonal antibody J. Nucl. Med. 42 121P2P
55. Zalutsky M R and Bigner D D 1996 Radioimmunotherapy with alpha-particle emitting radioimmunoconjugates Acta Oncol. 35 3739
56. 211At-labeled chimeric antitenascin monoclonal antibody 81C6 J. Nucl. Med. 49 308
57. 211At-labeled monoclonal antibodies Nucl. Med. Biol. 34 77985 (Pubitemid 47505399)